ADBICA

ADBICA

Clinical data
ATC code	none
Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide
CAS Number	1445583-48-1 Y
PubChem (CID)	72710773
ChemSpider	29342130
UNII	Q71G788A6H
Chemical and physical data
Formula	C20H29N3O2
Molar mass	343.46 g/mol
3D model (Jmol)	Interactive image
SMILES CCCCCN1C=C(C2=CC=CC=C21)C(=O)NC(C(=O)N)C(C)(C)C
InChI InChI=1S/C20H29N3O2/c1-5-6-9-12-23-13-15(14-10-7-8-11-16(14)23)19(25)22-17(18(21)24)20(2,3)4/h7-8,10-11,13,17H,5-6,9,12H2,1-4H3,(H2,21,24)(H,22,25) Key:IXUYMXAKKYWKRG-UHFFFAOYSA-N

ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013.^[1] ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.^[2] ADBICA is a potent agonist of the CB₁ receptor and CB₂ receptor with a EC₅₀ value of 0.69 nM and 1.8 nM respectively.^[3]

Legal Status

As of October 2015 ADBICA is a controlled substance in China.^[4]

See also

References

1. ↑ Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. 31: 223–240. doi:10.1007/s11419-013-0182-9. 
2. ↑ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980
3. ↑ Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alxendra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience. 6: 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475. 
4. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.